Paratek Closes $60 Million Loan Using Zai Lab Royalties for Pay Off

Boston's Paratek Pharma closed a $60 million non-recourse loan with an affiliate of R-Bridge Healthcare that will be paid off by royalties from Paratek's China omadacycline out-licensing agreement with Zai Lab. In May 2020, Zai filed an NDA for Paratek's omadacycline, an antibiotic, that was accepted by China 's NMPA for priority review. Omadacycline was tested as a treatment for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections. R-Bridge is part of China 's CBC Group (formerly C-Bridge Capital). More details.... Stock Symbols: (NSDQ: PRTK) (NSDQ: ZLAB; HK: 9688) Share this with colleagues: // //